Metastatic Pancreatic Adenocarcinoma Clinical Trial
— SEQUENCEOfficial title:
A Phase I/II Study of Nab-paclitaxel (Abraxane) and Gemcitabine Followed by Modified FOLFOX (AG-mFOLFOX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Verified date | September 2023 |
Source | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety and efficacy of nab-paclitaxel (Abraxane) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma
Status | Completed |
Enrollment | 168 |
Est. completion date | April 2021 |
Est. primary completion date | April 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histologically and/or cytologically confirmed pancreatic adenocarcinoma 2. Stage IV disease (metastatic only) 3. No prior systemic therapy for their diagnosis (except in adjuvant/neoadjuvant setting>six months previously) 4. ECOG performance status of 0-1 5. At least 18 years of age 6. Evidence of either or both of the following RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter = 20mm using conventional techniques or =10 mm with spiral CT scan) 7. Female patients must be either surgically sterile or postmenopausal, or if of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment and agree to use effective barrier contraception during the period of therapy. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the investigator. 8. Adequate bone marrow function: - ANC = 1500/uL - platelet count = 100,000/uL - hemoglobin = 9.0 g/dL 9. Adequate hepatic function: - Total bilirubin = 1.5 X ULN - AST (SGOT) = 2.5 X ULN - ALT (SGPT) = 2.5 X ULN 10. Adequate renal function as determined by either: - Calculated or measured creatinine clearance = 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used). 11. Ability to understand the nature of this study protocol and give written informed consent. 12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: 1. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study. 2. Presence of central nervous system or brain metastases. 3. Life expectancy < 12 weeks 4. Pregnancy (positive pregnancy test) or lactation. 5. Pre-existing sensory neuropathy > grade 1. 6. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months. 7. Major surgery and/or radiotherapy within 4 weeks of the start of study treatment, without complete recovery. 8. Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years. |
Country | Name | City | State |
---|---|---|---|
Spain | Spanish Cooperative for Digestive Tumour Therapy (TTD) | Madrid |
Lead Sponsor | Collaborator |
---|---|
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | microRNA expression levels and their correlation with tumour-efficacy parameters | 54 months | ||
Other | Biomarker determination (tissue sample at basal point and blood samples at basal and at the end of treatment). Correlation with treatment response | 54 months | ||
Primary | Dose-limiting toxicity for the AG-mFOLFOX combination | Primary outcome phase I. | 12 weeks | |
Primary | Rate of overall survival al 12 months | Primary outcome phase II | 12 weeks | |
Secondary | Rate of overall survival at 6 months | 54 months | ||
Secondary | Rate of overall survival at 24 months | 54 months | ||
Secondary | Time to tumor progression | 54 months | ||
Secondary | Progression free survival | 54 months | ||
Secondary | Overall Survival | 54 months | ||
Secondary | Objective radiographic response | Secondary outcome Phase I and Phase II | 54 months | |
Secondary | CA 19-9 biomarker response | 54 months | ||
Secondary | Safety profile of this combination (AG-mFOLFOX) using NCI-CTCAE v.4 criteria | Secondary outcome Phase I and Phase II | 54 months | |
Secondary | To assess the Quality of Life of the patients through the EORTC QLQ-C30/PAN26 and EORTC QLQ-CIPN20 questionnaires | Secondary outcome Phase I and Phase II | 54 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01964287 -
First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
|
Phase 1/Phase 2 | |
Completed |
NCT02826486 -
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)
|
Phase 2 | |
Active, not recruiting |
NCT04524702 -
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02890355 -
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04652206 -
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04132505 -
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT00998322 -
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04514497 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02562898 -
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Completed |
NCT01896869 -
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03337087 -
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02677038 -
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02985125 -
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05383352 -
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
|
Phase 1 | |
Completed |
NCT03943667 -
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
Completed |
NCT02436668 -
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
|
Phase 3 | |
Completed |
NCT01360853 -
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
|
Phase 3 | |
Completed |
NCT01124786 -
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
|
Phase 2 |